Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.42% is 37% below its 5-year average of -27.96%, near the low end of its 5-year range (-44.39%–-15.86%).
19.48% below its 12-month average of -32.16%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.40%.
RETURN ON ASSETS (ROA)
-38.42%
RETURN ON ASSETS (ROA) AVG TTM
-32.16%
RETURN ON ASSETS (ROA) AVG 3Y
-31.63%
RETURN ON ASSETS (ROA) AVG 5Y
-27.96%
RETURN ON ASSETS (ROA) AVG 10Y
-36.99%
RETURN ON ASSETS (ROA) AVG 15Y
-31.74%
RETURN ON ASSETS (ROA) AVG 20Y
-35.52%
CURRENT VS TTM AVG
-19.48%
CURRENT VS 3Y AVG
-21.47%
CURRENT VS 5Y AVG
-37.44%
CURRENT VS 10Y AVG
-3.88%
CURRENT VS 15Y AVG
-21.06%
CURRENT VS 20Y AVG
-8.17%
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-45.83%
vs the sector median at left
Celldex Therapeutics, Inc.
Market Cap
$2.17B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
Market Cap
$2.11B
Return on Assets (ROA)
7.23%
TTM Avg
5.94%
3Y Avg
5.72%
5Y Avg
5.23%
Market Cap
$2.07B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.06B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.05B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.31B
Return on Assets (ROA)
13.20%
TTM Avg
13.52%
3Y Avg
17.46%
5Y Avg
11.53%
Market Cap
$2.02B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$2.02B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.01B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.17B | -38.42% | -32.16% | -31.63% | -27.96% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.23% | 5.94% | 5.72% | 5.23% |
| Alvotech (ALVO)vs › | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | -68.96% | 16.60% | -13.89% | -23.58% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 14.58% | 11.33% | 2.89% | -3.84% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.31B | 13.20% | 13.52% | 17.46% | 11.53% |
| Immunome, Inc. (IMNM)vs › | $2.02B | -44.98% | -76.52% | -94.59% | -76.85% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 39.65% | 19.63% | 0.51% | -8.90% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | -3.14% | -22.75% | -10.43% | -6.58% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | -11.00% | -5.98% | -9.46% | -10.43% |
ROA
-38.4%
ROE
-42.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -44.39% |
| 2024-12-31 | -19.92% |
| 2023-12-31 | -30.37% |
| 2022-12-31 | -31.84% |
| 2021-12-31 | -15.86% |
| 2020-12-31 | -25.35% |
| 2019-12-31 | -41.39% |
| 2018-12-31 | -97.03% |
| 2017-12-31 | -29.48% |
| 2016-12-31 | -33.53% |
| 2015-12-31 | -37.68% |
| 2014-12-31 | -47.61% |
| 2013-12-31 | -23.50% |
| 2012-12-31 | -47.09% |
| 2011-12-31 | -45.72% |
| 2010-12-31 | -2.30% |
| 2009-12-31 | -26.02% |
| 2008-12-31 | -68.06% |
| 2007-12-31 | -57.48% |
| 2006-12-31 | -33.14% |
| 2005-12-31 | -49.65% |
| 2004-12-31 | -28.83% |
| 2003-12-31 | -40.47% |
| 2002-12-31 | -39.25% |
| 2001-12-31 | -42.54% |
| 2000-12-31 | -34.57% |
| 1999-12-31 | -56.88% |
| 1998-12-31 | -228.19% |
| 1997-12-31 | -133.67% |
| 1996-12-31 | -62.79% |
